# Improving Vaccine Protection for Adults

> **NCT07527247** · PHASE2 · RECRUITING · sponsor: **Singapore General Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Immune System Responses and Trained Immunity After AS01 Administration
- Healthy Adult

## Interventions

- **BIOLOGICAL:** AS01 adjuvant (0.5 mL intramuscular)
- **BIOLOGICAL:** YF17D (Stamaril, Sanofi-Pasteur)
- **OTHER:** Placebo (NaCl 09%, 0.5mL)

## Key facts

- **NCT ID:** NCT07527247
- **Lead sponsor:** Singapore General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-06
- **Primary completion:** 2029-02-28
- **Final completion:** 2029-02-28
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07527247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07527247, "Improving Vaccine Protection for Adults". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07527247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*